[1]
|
赵鑫, 邓姗. 年轻未生育的早期乳腺癌患者内分泌治疗期间发生子宫内膜增生的管理策略探讨[J]. 生殖医学杂志, 2022, 31(5): 681-684.
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[3]
|
Soerjomataram, I. and Bray, F. (2021) Planning for Tomorrow: Global Cancer Incidence and the Role of Prevention 2020-2070. Nature Reviews Clinical Oncology, 18, 663-672. https://doi.org/10.1038/s41571-021-00514-z
|
[4]
|
刘斌亮, 谢宁, 欧阳取长. 早期HR阳性/HER2阳性乳腺癌的治疗选择与思考[J]. 中国临床新医学, 2022, 15(6): 482-487.
|
[5]
|
Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Evidence. Lancet, 394, 1159-1168. https://doi.org/10.1016/S0140-6736(19)31709-X
|
[6]
|
Lazzeroni, M., Puntoni, M., Guerrieri-Gonzaga, A., et al. (2023) Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Ne-oplasia: A 10-Year Follow-Up of TAM-01 Study. Journal of Clinical Oncology, 41, 3116-3121. https://doi.org/10.1200/JCO.22.02900
|
[7]
|
Tjan-Heijnen, V.C.G., Lammers, S.W.M., Geurts, S.M.E., et al. (2023) Extended Adjuvant Aromatase Inhibition after Sequential Endocrine Therapy in Postmenopausal Women with Breast Cancer: Follow-Up Analysis of the Randomised Phase 3 DATA Trial. eClinicalMedicine, 58, Article ID: 101901. https://doi.org/10.1016/j.eclinm.2023.101901
|
[8]
|
孙蓉. 内分泌干预治疗对于女性乳腺癌发生关联的荟萃分析[D]: [硕士学位论文]. 西宁: 青海大学, 2021.
|
[9]
|
郭宗儒. 以雌受体为靶标的骨质疏松治疗药雷洛昔芬[J]. 药学学报, 2021, 56(7): 2033-2038.
|
[10]
|
地里呼玛尔•吐鲁洪, 李欣芳. HR+/HER2−乳腺癌内分泌治疗的研究进展[J]. 东南国防医药, 2021, 23(4): 387-392.
|
[11]
|
黄汉生. 乳腺癌内分泌治疗进展[J]. 中国现代医生, 2020, 58(14): 178-181.
|
[12]
|
张杨梅, 周一舟, 王翔, 等. 内分泌治疗方法治疗乳腺癌的价值研究[J]. 中国保健营养, 2019, 29(19): 45.
|
[13]
|
吕丹, 吴云, 马飞. 2021年乳腺癌治疗新进展[J]. 肿瘤综合治疗电子杂志, 2022, 8(1): 85-93.
|
[14]
|
De Placido, S., Gallo, C., De Laurentiis, M., et al. (2018) Adjuvant Anastrozole versus Exemestane versus Letrozole, Upfront or after 2 Years of Tamoxifen, in Endocrine-Sensitive Breast Cancer (FATA-GIM3): A Randomised, Phase 3 Trial. The Lancet Oncology, 19, 474-485. https://doi.org/10.1016/S1470-2045(18)30116-5
|
[15]
|
Del Mas-tro, L, Mansutti, M, Bisagni, G., et al. (2021) Extended Therapy with Letrozole as Adjuvant Treatment of Postmenopau-sal Patients with Early-Stage Breast Cancer: A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncol-ogy, 22, 1458-1467. https://doi.org/10.1016/S1470-2045(21)00352-1
|
[16]
|
Cuzick, J., Sestak, I., Forbes, J.F., et al. (2020) Use of Anastrozole for Breast Cancer Prevention (IBIS-II): Long-Term Results of a Randomised Controlled Trial. Lancet, 395, 117-122. https://doi.org/10.1016/S0140-6736(19)32955-1
|
[17]
|
Gnant, M., Pfeiler, G., Steger, G.G., et al. (2019) Adjuvant Denosumab in Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer (ABCSG-18): Disease-Free Survival Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 339-351. https://doi.org/10.1016/S1470-2045(18)30862-3
|
[18]
|
詹和道, 姚江凌, 崔红旺. 地诺单抗对比双膦酸盐类治疗骨质疏松有效性和安全性的Meta分析[J]. 中国药房, 2023, 34(11): 1384-1388.
|
[19]
|
Johansson, A., Dar, H., van’t Veer, L.J., et al. (2022) Twenty-Year Benefit from Adjuvant Goserelin and Tamoxifen in Premenopausal Patients with Breast Cancer in a Controlled Randomized Clinical Trial. Journal of Clin-ical Oncology, 40, 4071-4082. https://doi.org/10.1200/JCO.21.02844
|
[20]
|
Robertson, J.F.R., Bondarenko, I.M., Trishkina, E., et al. (2016) Fulvestrant 500 mg versus Anastrozole 1 mg for Hormone Receptor-Positive Advanced Breast Cancer (Falcon): An International, Randomised, Double-Blind, Phase 3 Trial. Lancet, 388, 2997-3005. https://doi.org/10.1016/S0140-6736(16)32389-3
|
[21]
|
Wang, J., Cai, L., Song, Y., et al. (2023) Clinical Efficacy of Fulvestrant Versus Exemestane as First-Line Therapies for Chinese Postmenopausal Oestrogen-Receptor Posi-tive/Human Epidermal Growth Factor Receptor 2 -Advanced Breast Cancer (FRIEND Study). European Journal of Cancer, 184, 73-82. https://doi.org/10.1016/j.ejca.2023.02.007
|
[22]
|
阿迪莱•艾萨, 赵菁, 袁瑛. 乳腺癌内分泌治疗耐药机制的研究进展[J]. 解放军医学杂志, 2021, 46(7): 702-709.
|
[23]
|
夏雯, 王树森. 激素受体阳性乳腺癌靶向治疗进展[J]. 中国肿瘤临床, 2017, 44(13): 635-639.
|
[24]
|
Brandão, M., Maurer, C., Ziegelmann, P.K., et al. (2020) Endocrine Therapy-Based Treatments in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: System-atic Review and Network Meta-Analysis. ESMO Open, 5, E000842. https://doi.org/10.1136/esmoopen-2020-000842
|
[25]
|
Ditsch, N., Wöcke, A., Untch, M., et al. (2022) AGO Rec-ommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care, 17, 403-420. https://doi.org/10.1159/000524879
|
[26]
|
易宗毕. 《HR+/HER2−转移性乳腺癌患者内分泌治疗和靶向治疗: ASCO更新版指南》解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(4): 37-42.
|
[27]
|
Sledge Jr., G.W., Toi, M., Neven, P., et al. (2020) The Effect of Abemaciclib plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncology, 6, 116-124. https://doi.org/10.1001/jamaoncol.2019.4782
|
[28]
|
Zhang, Q.Y., Sun, T., Yin, Y.M., et al. (2020) MONARCH plus: Abemaciclib plus Endocrine Therapy in Women with HR+/HER2− Advanced Breast Cancer: The Multinational Randomized Phase III Study. Therapeutic Advances in Medical Oncology, 12. https://doi.org/10.1177/1758835920963925
|
[29]
|
Johnston, S.R.D., Harbeck, N., Hegg, R., et al. (2020) Abema-ciclib Combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology, 38, 3987-3998. https://doi.org/10.1200/JCO.20.02514
|
[30]
|
Rugo, H.S., O’Shaughnessy, J., Boyle, F., et al. (2022) Adjuvant Abemaciclib Combined with Endocrine Therapy for High-Risk Early Breast Cancer: Safety and Patient-Reported Out-comes from the monarchE Study. Annals of Oncology, 33, 616-627. https://doi.org/10.1016/j.annonc.2022.03.006
|
[31]
|
Sledge Jr., G.W., Toi, M., Neven, P., et al. (2017) MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+/HER2− Advanced Breast Cancer Who Had Pro-gressed While Receiving Endocrine Therapy. Journal of Clinical Oncology, 35, 2875-2884. https://doi.org/10.1200/JCO.2017.73.7585
|
[32]
|
Rugo, H.S., Lerebours, F., Ciruelos, E., et al. (2021) Alpelisib plus Fulvestrant in PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer after a CDK4/6 Inhibitor (BY-Lieve): One Cohort of a Phase 2, Multicentre, Open-Label, Non-Comparative Study. The Lancet Oncology, 22, 489-498.
https://doi.org/10.1016/S1470-2045(21)00034-6
|
[33]
|
Turner, N.C., Oliveira, M., Howell, S.J., et al. (2023) Capi-vasertib in Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine, 388, 2058-2070. https://doi.org/10.1056/NEJMoa2214131
|
[34]
|
Beaver, J.A. and Park, B.H. (2012) The BOLERO-2 Trial: The Ad-dition of Everolimus to Exemestane in the Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer. Future Oncology, 8, 651-657.
https://doi.org/10.2217/fon.12.49
|
[35]
|
Shao, Z., Cai, L., Wang, S., et al. (2021) 238P BOLERO-5: A Phase II Study of Everolimus and Exemestane Combinati on in Chinese Post-Menopausal Women with ER+/HER2− Advanced Breast Cancer. Annals of Oncology, 32, S463. https://doi.org/10.1016/j.annonc.2021.08.521
|
[36]
|
Connolly, R.M., Zhao, F., Miller, K.D., et al. (2021) E2112: Randomized Phase III Trial of Endocrine Therapy plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology, 39, 3171-3181. https://doi.org/10.1200/JCO.21.00944
|
[37]
|
Jiang, Z., Li, W., Hu, X., et al. (2019) Tucidinostat plus Exemestane for Postmenopausal Patients with Advanced, Hormone Receptor-Positive Breast Cancer (ACE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 806-815. https://doi.org/10.1016/S1470-2045(19)30164-0
|
[38]
|
Biello, F., Platini, F., D’Avanzo, F., et al. (2021) Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights. Biomolecules, 11, Article No. 125. https://doi.org/10.3390/biom11010125
|
[39]
|
Schmid, P., Cortes, J., Joaquim, A., et al. (2023) XENERA-1: A Randomised Double-Blind Phase II Trial of Xentuzumab in Combination with Everolimus and Exemestane versus Everolimus and Exemestane in Patients with Hormone Receptor-Positive/her2-Negative Metastatic Breast Cancer and Non-Visceral Disease. Breast Cancer Research, 25, Article No. 67. https://doi.org/10.1186/s13058-023-01649-w
|